Sanofi’s BTK Inhibitor Meets Primary Endpoint in Phase 2 Trial Amidst Criticism
By Ruchi Jhonsa, Ph.D. Sanofi today announced positive results for its phase 2b study analyzing a BTK inhibitor (SAR442168), an oral, brain penetrant small molecule used in treating patients with …
Read More